Arch Biopartners Stock Price To Sales

ARCH Stock  CAD 1.77  0.05  2.91%   
Arch Biopartners fundamentals help investors to digest information that contributes to Arch Biopartners' financial success or failures. It also enables traders to predict the movement of Arch Stock. The fundamental analysis module provides a way to measure Arch Biopartners' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arch Biopartners stock.
Last ReportedProjected for Next Year
Price To Sales Ratio 1.87  1.78 
Price To Sales Ratio is likely to drop to 1.78 in 2024.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Arch Biopartners Company Price To Sales Analysis

Arch Biopartners' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

P/S

 = 

MV Per Share

Revenue Per Share

More About Price To Sales | All Equity Analysis

Current Arch Biopartners Price To Sales

    
  83.08 X  
Most of Arch Biopartners' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arch Biopartners is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Arch Price To Sales Driver Correlations

Understanding the fundamental principles of building solid financial models for Arch Biopartners is extremely important. It helps to project a fair market value of Arch Stock properly, considering its historical fundamentals such as Price To Sales. Since Arch Biopartners' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arch Biopartners' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arch Biopartners' interrelated accounts and indicators.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Competition

Arch Price To Sales Ratio

Price To Sales Ratio

1.78

At this time, Arch Biopartners' Price To Sales Ratio is fairly stable compared to the past year.
Based on the latest financial disclosure, Arch Biopartners has a Price To Sales of 83 times. This is 288.2% higher than that of the Biotechnology sector and 15.58% lower than that of the Health Care industry. The price to sales for all Canada stocks is notably lower than that of the firm.

Arch Biopartners Current Valuation Drivers

We derive many important indicators used in calculating different scores of Arch Biopartners from analyzing Arch Biopartners' financial statements. These drivers represent accounts that assess Arch Biopartners' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Arch Biopartners' important valuation drivers and their relationship over time.
201920202021202220232024 (projected)
Market Cap82.1M104.9M187.1M6.8M6.1M5.8M
Enterprise Value84.8M109.6M191.0M8.5M7.6M7.2M

Arch Fundamentals

About Arch Biopartners Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Arch Biopartners's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arch Biopartners using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arch Biopartners based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Arch Stock Analysis

When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.